NEVRO CORP. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2020-12-03: Form 8-K; Period of report 2020-11-30; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events; Details 5.02.
- 2020-11-05: Form 8-K; Period of report 2020-11-05; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2020-08-05: Form 8-K; Period of report 2020-08-05; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2020-06-04: Form 8-K; Period of report 2020-06-04; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2020-12-03 | 8-K | 2020-11-30 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 On December 2, 2020, the Board of Directors (the “Board”) of Nevro Corp. (“Nevro” or the “Company”) appointed Susan E. Siegel to the Board effective immediately. 8.01 On December 3, 2020, Nevro issued a press release announcing Ms. Siegel’s appointment to the Board and Dr. Jaeger’s resignation. | nvro-8k_20201130.htm |
| 2020-11-05 | 8-K | 2020-11-05 | 2.02 Results of Operations and Financial Condition | 2.02 On November 5, 2020, Nevro Corp. (“Nevro” or the “Company”) issued a press release relating to its financial results for the three and nine months ended September 30, 2020. | nvro-8k_20201105.htm |
| 2020-08-05 | 8-K | 2020-08-05 | 2.02 Results of Operations and Financial Condition | 2.02 On August 5, 2020, Nevro Corp. (“Nevro” or the “Company”) issued a press release relating to its financial results for the three and six months ended June 30, 2020. | nvro-8k_20200805.htm |
| 2020-06-04 | 8-K | 2020-06-04 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On June 4, 2020, Nevro Corp. (“Nevro” or the “Company”) announced the appointment of Roderick (“Rod”) MacLeod as the Company’s Chief Financial Officer, effective as of June 15, 2020. | nvro-8k_20200604.htm |
| 2020-05-26 | 8-K | 2020-05-21 | 5.07 Submission of Matters to a Vote of Security Holders | nvro-8k_20200521.htm | |
| 2020-05-05 | 8-K | 2020-05-05 | 2.02 Results of Operations and Financial Condition | 2.02 On May 5, 2020, Nevro Corp. (“Nevro” or the “Company”) issued a press release relating to its financial results for the three months ended March 31, 2020. | nvro-8k_20200505.htm |
| 2020-04-13 | 8-K | 2020-04-09 | 8.01 Other Events | nvro-8k_20200409.htm | |
| 2020-04-07 | 8-K | 2020-04-01 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. 2.03 The information set forth under Item 1.01 of this Current Report on Form 8-K under the heading “Supplemental Indenture for the Notes” is incorporated by reference into this Item 2.03. 3.02 The Company entered into the Warrant Transactions with the Option Counterparties in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). | d924665d8k.htm |
| 2020-04-01 | 8-K | 2020-04-01 | 2.02 Results of Operations and Financial Condition | 2.02 On April 1, 2020, Nevro Corp. (“Nevro” or the “Company”) issued a press release relating to its preliminary unaudited financial results for the three months ended March 31, 2020, the Company’s suspension of its previously announced annual guidance for 2020 in light of the continued uncertainties resulting from the impact of COVID-19 and actions the Company has taken in response to COVID-19. | d912944d8k.htm |
| 2020-02-28 | 8-K | 2020-02-27 | 8.01 Other Events | 8.01 On February 27, 2020, Nevro Corp. (“Nevro” or the “Company”) entered into a settlement agreement in regards to its patent infringement lawsuit against Stimwave Technologies, Inc. filed in the United States District for the District of Delaware (the “Delaware District Court”) on February 14, 2019. | d872193d8k.htm |
| 2020-02-25 | 8-K | 2020-02-25 | 2.02 Results of Operations and Financial Condition | 2.02 On February 25, 2020, Nevro Corp. (“Nevro” or the “Company”) issued a press release relating to its financial results for the three months and full year ended December 31, 2019. | nvro-8k_20200225.htm |
| 2020-01-14 | 8-K | 2020-01-14 | 2.02 Results of Operations and Financial Condition | nvro-8k_20200114.htm | |
| 2020-01-08 | 8-K | 2020-01-06 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 6, 2020, Nevro Corp. (the “Company”) and Doug Alleavitch, the Company’s Vice President, Quality, mutually agreed upon his separation from the Company. | d810396d8k.htm |